导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.37% | 1346/4773 |
| 近一周 | -0.66% | 1697/5467 |
| 近一月 | -5.83% | 2632/5421 |
| 近一季 | -9.91% | 3170/5238 |
| 近半年 | -2.66% | 2410/4931 |
| 近一年 | 7.41% | 1291/4400 |
| 近两年 | 70.04% | 1010/2954 |
| 近三年 | 36.71% | 835/2253 |
| 成立以来 | 61.29% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.29% 978/4961 |
18.21% 1407/5312 |
- - |
- - |
| 2025 | 28.96% 1435/4813 |
1.94% 1508/3635 |
1.74% 2191/4076 |
23.16% 1569/4524 |
0.95% 1641/4813 |
| 2024 | 6.39% 1760/3463 |
-2.65% 1400/2808 |
-5.09% 1645/3014 |
15.22% 1782/3129 |
-0.06% 1304/3463 |
| 2023 | -6.23% 824/2656 |
7.09% 606/2280 |
-4.12% 1061/2385 |
-4.59% 1173/2515 |
-4.28% 949/2655 |
| 2022 | -18.42% 705/2207 |
-13.32% 735/1919 |
2.59% 1282/2016 |
-10.37% 390/2113 |
2.35% 963/2208 |
| 2021 | 14.00% 345/1822 |
-1.96% 561/1255 |
8.61% 611/1330 |
4.02% 387/1466 |
2.92% 496/1822 |
| 2020 | 21.71% 687/1250 |
-3.62% 312/1028 |
16.61% 426/1067 |
5.63% 902/1164 |
2.52% 984/1184 |
| 2019 | - - |
- - |
-7.05% 538/788 |
1.87% 347/850 |
6.33% 626/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 方正富邦中证500ETF联接A VS. 长安沪深300非周期A(740101) |